Merck & Co. isn’t resting on Keytruda’s laurels. But an attempt to improve on the undoubtful cancer immunotherapy king with another agent has failed in …
BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors as a potential cornerstone of combination cancer therapy, announces that the first …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
